In a startling turn of events, AstraZeneca finds itself entangled in a web of controversy as it faces stern scrutiny from the United Kingdom’s drug marketing watchdog, the Prescription Medicines Code of Practice Authority (PMCPA). The cause of this uproar stems from a Symbicort advertisement, which, it has been ruled, displayed serious lapses in judgment by the pharmaceutical giant.
The complaint that ignited this investigation was filed by an anonymous healthcare professional who chanced upon an advertisement for AZ’s immensely popular respiratory medication, Symbicort, in MIMS. MIMS stands as the foremost reference manual for prescription and generic drugs, catering to both patients and healthcare practitioners in the UK.
The advertisement so profoundly irked the healthcare professional that they took the formal route, submitting a complaint to the PMCPA. This regulatory body oversees the Association of the British Pharmaceutical Industry’s code, which serves as the comprehensive guidebook for drug marketing practices within Britain.
The PMCPA’s verdict was unequivocal, with a total of six code breaches attributed to AstraZeneca, an unusually high number by industry standards. Most significantly, AstraZeneca was found guilty of a severe breach under Clause 2 of the code, a clause reserved for actions that “bring discredit upon, and reduce confidence in, the industry.”
The crux of the matter revolved around AstraZeneca’s portrayal of the use of Symbicort in its advertisement.
Also Read: Roche Fined For Serious Breach Of Marketing Code By Failing To Disclose Safety Data
The first and conspicuous violation lay in the fact that the advertisement, as published in the print edition of MIMS, failed to provide any reference to the location of prescribing information on the page, rendering it practically invisible as per PMCPA’s judgement.
Even more critically, the PMCPA determined that the ad “misleadingly implied” that all variants of Symbicort were suitable for both maintenance and reliever therapy, a medical practice known as MART. In reality, Symbicort 400/12 is intended solely for maintenance therapy. The PMCPA expressed its dissatisfaction, deeming the fine print at the very bottom of the page inadequate in rectifying the misleading impression.
Also Read: Croma Pharma Faces Backlash For Lavish Launch Of New Botox Rival
In a telling statement, the PMCPA’s panel underscored that the use of the higher Symbicort dose (400/12) for reliever therapy could potentially jeopardize patient safety, thereby finding AstraZeneca in violation of Clause 2, an alarming verdict.
This development follows closely on the heels of reprimands issued to Roche and Novartis earlier this month by the PMCPA, both of which were chastised for Clause 2 breaches. These Swiss pharmaceutical giants now find themselves in the unenviable position of being repeat offenders in this regard.
